

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Diagnostics Assessment Programme

Diagnosis and monitoring of sepsis: procalcitonin testing (ADVIA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive Kryptor assay, Elecsys BRAHMS PCT assay, LIAISON BRAHMS PCT assay and VIDAS BRAHMS PCT assay)

Provisional stakeholder list

Manufacturer(s) Thermo Fisher Scientific Siemens Healthcare Diagnostics BioMerieux UK Ltd Roche Diagnostics
Manufacturer(s) of related technologies (not included in scope) Spectral Platforms
Professional groups Royal College of Pathologists Intensive Care Society Royal College of Physicians Royal College of Nursing British Infection Association
Patient/carer groups Group B Strep MRSA Action UK Children's Cancer and Leukaemia Group UK Sepsis Trust Meningitis Research Foundation
Research groups Integrated Medicines Ltd Manchester Centre for Health Economics, The University of Manchester National Clinical Guidelines Centre
External Assessment Group Kleijnen Systematic Reviews
Others Department of Health Healthcare Improvement Scotland NHS England Welsh Government

Definitions:**Stakeholders**

Individuals or organisations interested in a topic being evaluated by the Diagnostics Assessment Programme, and who register to become a stakeholder. For example, manufacturers of the technology, national organisations that represent healthcare professions who operate or use the results of the technology, national patient or carer organisations, NHS service providers and commissioners, statutory organisations and research organisations.

External Assessment Group (EAG)

An independent academic group commissioned by the NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC) that prepares a systematic review of the clinical and cost effectiveness of the technology(ies).